BioAesthetics Files IPO Prospectus for Customizable, Immune-Rejection-Free Nipple-Areola Complex Regeneration Using Collagen Scaffold Technology

As the crucial final step in breast reconstruction surgery, nipple-areola complex (NAC) reconstruction is of paramount importance. A morphologically complete NAC structure holds immeasurable value in promoting patients’ psychological well-being and enhancing their quality of life. With rapid advancements in medical aesthetic technologies, the field of NAC reconstruction is ushering in unprecedented opportunities for innovation and development.

BioAesthetics, since its establishment in 2015, has been dedicated to expanding the boundaries of breast reconstruction following mastectomy for breast cancer patients. Its core vision is to optimize reconstructive options for patients, delivering a more personalized and natural recovery experience.BioAesthetics’ pioneering achievement—the tissue-engineered nipple-areola complex (NAC) product—is an acellular NAC graft that, through the migration, proliferation, and differentiation of the patient’s own cells, ultimately forms a nipple-areola structure that seamlessly integrates into the patient’s body.

In breast reconstruction surgery, immediately following mastectomy, physicians can precisely implant BioAesthetics’ NAC graft into the patient’s reconstructed breast. Subsequently, the patient’s own physiological mechanisms recognize this graft as a growth template, initiating a natural repair process that gradually regenerates the patient’s own nipple-areola complex tissue.

BioAesthetics, a company spun out of Tulane University—known as the “Harvard of the South”—by Dr. Nicholas Pashos in 2015, has carried the mission of revolutionizing medical technology since its inception. In 2017, BioAesthetics successfully joined IndieBio, the world’s leading biotechnology accelerator based in San Francisco, California, further accelerating its exploration in the field of biomedical engineering.

Dr. Nicholas Pashos, an NSF IGERT Fellow and founder of BioAesthetics, identified a significant unmet need and the limitations of existing solutions in the field of post-mastectomy nipple reconstruction while pursuing his Ph.D. in Biological Innovation at Tulane University. For instance, although prosthetic reconstruction can mimic the shape of a nipple, its texture, color, and tactile feel often differ significantly from those of a natural nipple, failing to meet patients’ expectations for realism and aesthetics. Furthermore, prostheses may cause complications such as rejection, displacement, or deformation, necessitating regular maintenance and replacement.

Reflecting on the original intention behind founding BioAesthetics, Dr. Pashos recalled, “I was once dedicated to research on whole-lung regeneration, but a chance encounter drew my attention to the issue of nipple loss. The documentary Becoming Chaz made me realize that countless individuals lose their nipple-areola complex (NAC) every year, the majority of whom are breast cancer patients. This inspired me to harness the power of biomedical engineering to improve the quality of life for these patients.”

BioAesthetics’ NACgraft product is a bio-derived collagen scaffold that uniquely mimics the natural morphology of the nipple-areola complex (NAC), seamlessly integrates with the patient’s body, promotes autologous cell growth and regeneration, and ultimately achieves authentic NAC reconstruction.

Similar to breast reconstruction, nipple-areola complex (NAC) reconstruction offers significant physiological and psychological benefits to patients undergoing mastectomy for breast cancer. For those who opt for breast reconstruction, they can select NACgraft(s) tailored to their desired size and shape as part of the final stage of their breast reconstruction journey. Unlike traditional tissue or organ transplantation, which requires immunosuppressive medication, patients who choose NACgraft do not need to take immunosuppressants.

According to BioAesthetics’ official disclosure, NACgrafts encourage the patient’s own cells to grow into the NACgraft and transform it into living NAC.The patient’s new NAC is living tissue that “looks and feels authentic.” Moreover, the personalized customization features of NACgraft enable patients to select the NAC shape and size that best suit their individual needs and preferences, serving as the perfect culmination of their breast reconstruction journey.

As a scalable technology platform, collagen scaffolds are not only applicable to nipple-areola complex regeneration but also enable the fabrication of novel grafts for treating various wound types. Consequently, BioAesthetics has not limited its scope to the field of breast reconstruction.

First is the exploration in the field of pelvic organ prolapse (POP) treatment.In 2021, BioAesthetics received a $256,000 grant from the U.S. Eunice Kennedy Shriver National Institute of Child Health and Human Development to develop a novel transplant technique for the treatment of pelvic organ prolapse (POP).

Female pelvic organ prolapse is a prevalent health issue that significantly impacts women's quality of life. This condition primarily arises from weakened support functions of the pelvic floor muscles or connective tissues, leading to the descent and potential protrusion of pelvic organs such as the bladder, uterus, and rectum outside the body. According to WHO data, 33% to 50% of women worldwide are affected by pelvic organ prolapse (POP) to varying degrees, with symptoms including urinary incontinence, frequent urinary tract infections, bleeding, and pain in the pelvic region.

For patients with severe symptoms or those whose quality of life is affected, surgery is often a necessary treatment option. However, traditional surgical approaches for pelvic organ prolapse (POP), such as the use of sutures, synthetic mesh implants, or graft tissues to provide support, may restore the anatomical position of pelvic organs to some extent, but their success rates are less than ideal. Moreover, these methods carry a range of safety risks, particularly with the use of synthetic mesh implants, which can lead to serious complications including chronic infection, nerve and tissue damage, and genital erosion.

Female pelvic organ prolapse is a condition in which the pelvic floor muscles or connective tissues fail to support the pelvic organs. Globally, this condition affects 33% to 50% of women. Patients frequently experience urinary incontinence, recurrent urinary tract infections, bleeding, and pain. Approximately 12% of women with this condition require surgical intervention to restore the organs to their anatomical positions. The procedure typically employs sutures, synthetic mesh implants, or graft tissues to provide support. However, surgical success rates are low. Furthermore, synthetic mesh carries significant safety risks, including chronic infection, nerve and tissue damage, and genital erosion.

BioAesthetics’ biodegradable, biocompatible polymer-enhanced acellular biological grafts are poised to address many of the shortcomings of current pelvic organ prolapse (POP) treatments, such as low surgical success rates and significant safety risks associated with synthetic meshes.. Nicholas Pashos, founder of BioAesthetics, also stated, “BioAesthetics is leveraging biomaterial technology to design effective therapies that match the properties of healthy tissues within the pelvic floor.”

Next is the development of novel grafts for the treatment of pressure ulcers. Currently, BioAesthetics is conducting tests in collaboration with Tulane University.。

BioAesthetics disclosed,The new generation of grafts not only features a more robust structure and provides sustained drug release at the surgical site to combat infection, but also promotes rapid cell growth and wound healing by utilizing decellularized tissue as a collagen scaffold, offering new therapeutic hope for patients with pressure ulcers.。

To validate the efficacy of this novel graft in the treatment of pressure ulcers, a research team at Tulane University is conducting a series of rigorous tests. The researchers are focusing on the graft’s drug-release performance over 14 days, the in vitro drug release and bioactivity, and an evaluation of its efficacy against antibiotic-resistant bacteria in mouse models.

BioAesthetics has grown rapidly under the incubation of IndieBio, achieving significant milestones in fundraising, headquarters relocation, and product development. Since successfully completing its financing round in 2017, the company has continued to expand and relocated its headquarters to North Carolina’s Research Triangle Park in 2018.

In 2020, BioAesthetics reached a fundraising peak, achieving its $2.5 million Series A financing target; in 2021, the company doubled its fundraising goal to $5 million to accelerate the commercialization of NACgraft acellular dermal matrix.

Emi Gonzalez, Venture Partner at Social Starts and Joyance Partners, stated, “BioAesthetics addresses significant unmet medical needs in women’s health, offering solutions that are far superior and more cost-effective than any others currently on the market. We are delighted to support the BioAesthetics team in building this innovative regenerative medicine company.”

BioAesthetics has not only achieved success in the financing market but also made remarkable strides in its product pipeline.In 2021, BioAesthetics conducted a clinical study on the NACgraft nipple reconstruction graft at Stanford Medicine.It is reported that researchers conducted a 12-month follow-up study of 15 patients who had undergone BioAesthetics NACgraft nipple reconstruction, having previously received autologous breast reconstruction, to evaluate the efficacy and patient satisfaction of NACgraft in breast reconstruction.

In the field of breast regeneration, in 2022, the domestic innovative enterprise Zhenghai Biotechnology also initiated clinical trials for its "breast patch." This clinical study, led by Professor Wu Jiong from Fudan University Shanghai Cancer Center, aims to evaluate the efficacy and safety of the breast patch for soft tissue reinforcement in breast reconstruction surgery.

It is understood that breast patches are xenogeneic acellular dermal matrices prepared from bovine skin tissue through a series of processing steps. Their main component is collagen, which retains its unique three-dimensional spatial structure. Compared with traditional implant-based breast reconstruction, this approach offers advantages such as improved expansion of the lower pole, reduced postoperative pain, enhanced aesthetic outcomes, and shortened operative time.